All Articles

Along with survivor mentors are other caring individuals who desire to make a positive impact by volunteering to support people with cancer; this year, you can become an advocate, too!

A look back at all the novel approvals in oncology made by the FDA in 2024.

Oncology nurse navigator involvement in the management of patients receiving oral oncolytic therapy can increase the quality of patient care by advancing patient understanding of their medication, limiting side effects, and improving adherence.

In an interview with Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG, we learn how enhanced healthcare provider communication skills can improve patients’ quality of life and confidence to navigate the complexities of end-of-life care.

Whether they are currently undergoing breast cancer treatment, supporting a loved one, or seeking to become a community ally, the Tigerlily Foundation’s ANGEL Advocacy Program can offer people comprehensive advocacy training, educational resources, and the support of a warm community.

A precise and comprehensive understanding of survivorship and its phases is essential for improving patient care throughout their cancer journey.

Awardees Honored at the AONN+ Annual Conference Highlighting awardees honored at the 2024 AONN+ Annual Conference.

Langhorne, PA – January 16, 2025 - The Journal of Oncology Navigation & Survivorship (JONS), Amplity’s premier oncology navigation journal, and the Tigerlily Foundation (Tigerlily) have partnered to advance two innovative health equity initiatives: comprehensive breast cancer advocacy training and clinical trial education and community engagement. Both efforts aim to address the unique and often overlooked needs of Black, Brown, and underserved women facing breast cancer, with a focus on creating lasting change within these communities.

This article summarizes 2 analyses from the phase 3 GMMG-HD7 trial presented at ASH 2024, as well as the FDA’s Oncologic Drugs Advisory Committee support for the use of minimal residual disease as an accelerated approval endpoint in multiple myeloma clinical trials.

In this article, the results from 2 studies of Isa-KRd in newly diagnosed multiple myeloma (NDMM) are summarized, with the GMMG-CONCEPT trial focusing on high-risk NDMM and the IFM 2020-02 MIDAS study focusing on transplant-eligible NDMM.